Key Highlights

Eli Lilly's Thursday, October 29, 2026 report faces USD 88.68 billion of full-year revenue consensus, above a company range that starts at USD 85 billion and ends at USD 87 billion, after the stock lost roughly 3.3% Friday.

Moderna traded near USD 193.62 on October 23, about 4% below its prior level, after Thursday readings showed a 17.6% to 25% loss linked to apparently leaked Phase 3 melanoma-vaccine results.

A 20.1% fall left Corcept at USD 85.86. Genmab, meanwhile, rose 9.5% after releasing Phase 3 findings for competing ovarian-cancer treatment Rina-S.

The shared issue is the starting bar: Moderna had climbed almost 600% during the year by early October, Lilly consensus exceeds its own outlook, and Corcept's expansion case relied heavily on one oncology opportunity.

Must Eli Lilly Raise Guidance Again to Satisfy the Market?

The two biotechnology selloffs show why the October 29, 2026 third-quarter release from Eli Lilly (NYSE:LLY) may need more than a conventional beat. Analysts project about USD 22.62 billion of sales, representing 28.5% year-over-year growth. Their USD 88.68 billion full-year view exceeds the company's upper boundary by USD 1.68 billion. Management starts its twice-raised outlook at USD 85 billion, with USD 87 billion marking the ceiling.

Methodology puts the low EPS forecast at USD 5.38 and the high one at USD 6.67, while options imply an approximately 6.6% move in either direction. Charges for acquired IPR&D explain much of that dispersion because Lilly counts the deal expense in non-GAAP results. Such cost reduced second-quarter EPS by USD 3.03, yet adjusted earnings still reached USD 8.38 compared with consensus near USD 6.58. Over one month, normalized consensus moved from around USD 9.87 to roughly USD 6.67, a decline calculated at about USD 3.20.

Revenue may therefore offer the cleaner signal. Second-quarter US prices declined roughly 9% after excluding rebate adjustments, whereas international Mounjaro sales advanced 172%. Further domestic price pressure or competitive action from Novo Nordisk, whose ticker is (NYSE:NVO), could constrain margins despite higher volume. Historical reactions show the danger: Lilly fell 14.14% on its second-quarter 2025 reporting day even with an EPS beat. With expectations beyond the issued range, respectable numbers without a third guidance increase may still disappoint. Revenue composition, pricing and the outlook may each matter more than a single earnings line, and no result can be known beforehand.

Why Did Successful Melanoma Data Still Hurt Moderna?

Moderna (NASDAQ:MRNA) traded around USD 193.62 during Friday morning, October 23, 2026, a decline of approximately 4%. It followed a Thursday selloff reported at 17.6% to 25%, with the exact measure depending on timing, after an apparent premature disclosure of Phase 3 melanoma findings. Intismeran autogene is a personalized cancer vaccine developed with Merck, tagged (NYSE:MRK), and used alongside Keytruda.

The combination lowered the chance of melanoma recurrence or death versus Keytruda by itself. Its benefit came close to analyst forecasts but below the most optimistic assumptions, and it was smaller than the effect in an earlier, smaller study conducted in a different patient population. That distinction mattered because the Phase 3 program had already met its primary objective on Wednesday, August 19, 2026. By early October, the initial news had helped Moderna accumulate almost 600% of appreciation during the year.

Investors at that price had assumed a large effect and potential use across several cancers. A positive but more modest outcome reduces estimates of peak revenue as physicians and payers judge the extra contribution from a costly vaccine made individually for each patient. The apparent leak also removed the orderly conference presentation investors expected. Madrid hosted the complete ESMO presentation during the weekend, including survival curves and subgroup results. Merck reports before Thursday's opening on October 29, the same date as Lilly, while volatility, manufacturing cost and a possibly modest confirmed benefit remain the principal risks.

How Did a Rival's Survival Result Reprice Corcept?

Corcept Therapeutics (NASDAQ:CORT) ended Friday at USD 85.86, a 20.1% decline and one of the session's largest losses. The catalyst originated with Genmab (NASDAQ:GMAB), which gained 9.5% after saying rinatabart sesutecan, or Rina-S, improved both progression-free and overall survival in platinum-resistant ovarian cancer. Its Phase 3 comparison against chemotherapy was associated with a 57% reduction in death risk.

Corcept's relacorilant blocks cortisol effects and has FDA approval within a combination for the same disease. Commercial value depends on the number of treatable patients, pricing and the time a medicine remains a leading choice. Platinum-resistant ovarian cancer has relatively few options, allowing a newly cleared drug to gain share quickly when competition is constrained. A rival that prolongs life changes that calculation because doctors and treatment guidelines commonly give survival outcomes greater weight.

Friday's 20.1% fall is therefore consistent with a reduction in expected peak ovarian-cancer revenue rather than a rejection of relacorilant's own evidence. The next uncertainty is timing, since complete Genmab results and a regulatory submission will indicate how soon Rina-S might reach patients. Sequencing or combining the medicines could make the commercial overlap smaller than the market reaction suggests. Conversely, a reduced oncology opportunity would place more of Corcept's valuation on its established cortisol business.

What to Watch Next: Can October 26 Data and October 29 Earnings Reset Expectations?

All three stocks are trading against assumptions set before the next evidence arrives. Moderna lost ground on clinically positive melanoma findings because the nearly 600% advance had embedded a larger benefit. Corcept's 20.1% drop followed a competitor's survival success that narrowed its presumed market. Lilly approaches the same mechanism from another direction: annual consensus stands USD 1.68 billion above company guidance, so a standard beat may not be enough.

The sequence starts Monday, October 26, with the response to full ESMO data. Wednesday, October 28 and its Fed decision come next. Lilly and Merck both release results Thursday, October 29. Midterm voting follows on November 3, 2026, a Tuesday. Those events can affect clinical assumptions, growth forecasts, discount rates and drug-pricing policy in quick succession.

Trial success does not by itself establish regulatory approval or future sales, and consensus is a forecast rather than a company promise. Lilly's possible guidance change, Moderna's detailed subgroup evidence and Genmab's filing plans should each be judged against the expectation already reflected in price. This material does not provide investment advice.